Hemophilia is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. It is caused by a gene defect that decides how factors VIII, IX, or XI are produced by the body. One of the Hemophilia type is Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by missing or defective factor IX, a clotting protein. Although it is passed down from parents to children, about one-third of cases are caused by a spontaneous mutation, a change in a gene. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing.

 

“Hemophilia B Pipeline Insight, 2023” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia B market. A detailed picture of the Hemophilia B pipeline landscape is provided, which includes the disease overview and Hemophilia B treatment guidelines.

 

Request for free sample Report: https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight

 

Some of Hemophilia B companies covered:

• Novo Nordisk
• CSL Behring
• Bioverativ Therapeutics
• UniQure
• Pfizer
• Freeline Therapeutics
• Belief BioMed
• Amarna therapeutics
• Sanofi
• Centessa Pharmaceuticals
• Catalyst Biosciences
• Amarna therapeutics
• And Many Others

 

Some of Hemophilia B Drugs covered:

• Rebinyn
• AMA005
• CB 2679d-GT
• SerpinPC
• Concizumab
• Fitusiran
• BBM-H901
• Idelvion
• Alprolix
• Etranacogene dezaparvovec (AMT-061)
• Fidanacogene elaparvovec
• FLT180a
• And Many Others

 

Request for free sample Report: https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight

 

Hemophilia B Pipeline Report Highlights:

• The Hemophilia B report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hemophilia B across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Hemophilia B therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Hemophilia B research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hemophilia B.

 

Request for free sample Report: https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight

 

Table of Contents:

1. Report Introduction

2. Hemophilia B 

3. Hemophilia B Current Treatment Patterns

4. Hemophilia B – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hemophilia B Late Stage Products (Phase-III)

7. Hemophilia B Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hemophilia B Discontinued Products

13. Hemophilia B Product Profiles

14. Hemophilia B Key Companies

15. Hemophilia B Key Products

16. Dormant and Discontinued Products

17. Hemophilia B Unmet Needs

18. Hemophilia B Future Perspectives

19. Hemophilia B Analyst Review  

20. Appendix

21. Report Methodology

 

Latest Reports:

Bronchial Spasm Market

DelveInsight’s “Bronchial Spasms Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Bronchial Spasms, historical and forecasted epidemiology as well as the Bronchial Spasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services